Skip to main content
Top
Published in: Endocrine 3/2022

Open Access 29-07-2022 | Insulins | Original Article

Newly diagnosed diabetes mellitus is a risk factor for cardiocerebrovascular events in primary aldosteronism

Authors: Cui Zhang, Yiran Jiang, Tingwei Su, Lei Jiang, Weiwei Zhou, Xu Zhong, Luming Wu, Weiqing Wang

Published in: Endocrine | Issue 3/2022

Login to get access

Abstract

Objective

To explore the prevalence and clinical significance of newly diagnosed diabetes mellitus (DM) in patients with primary aldosteronism (PA). Investigating the risk factors for cardiocerebrovascular disease (CCVD) will guide strategies for reducing CCVD in patients with PA.

Methods

We retrospectively included 729 PA patients without DM and conducted oral glucose tolerance tests.

Results

We found that 15.0% of PA patients had newly diagnosed DM. The DM prevalence increased with elevated aldosterone levels [OR = 3.20 (1.77, 5.78), P value < 0.001]. The rate of CCVD in newly diagnosed diabetic PA patients was higher than that in nondiabetic PA patients at diagnosis (11.9% vs. 5.0%, P = 0.005). Furthermore, multivariate logistic analysis revealed that HT duration [1.055 (1.002,1.111), P = 0.041] and newly diagnosed DM [2.600 (1.072,6.303), P = 0.034] were significantly associated with CCVD in PA patients.

Conclusion

The prevalence of newly diagnosed DM in PA patients was higher than that in the general population. Aldosterone level was an independent risk factor for DM not for CCVD. CCVD was correlated with longer HT duration and newly diagnosed DM. Therefore, it is crucial to screen DM at the diagnosis in PA patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference X. Sang, Y. Jiang, W. Wang, L. Yan, J. Zhao, Y. Peng, W. Gu, G. Chen, W. Liu, G. Ning, Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J. Hypertens. 31(7), 1465–1471 (2013). discussion 1471-1462CrossRef X. Sang, Y. Jiang, W. Wang, L. Yan, J. Zhao, Y. Peng, W. Gu, G. Chen, W. Liu, G. Ning, Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J. Hypertens. 31(7), 1465–1471 (2013). discussion 1471-1462CrossRef
2.
go back to reference S. Monticone, J. Burrello, D. Tizzani, C. Bertello, A. Viola, F. Buffolo, L. Gabetti, G. Mengozzi, T.A. Williams, F. Rabbia, F. Veglio, P. Mulatero, Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 69(14), 1811–1820 (2017)CrossRef S. Monticone, J. Burrello, D. Tizzani, C. Bertello, A. Viola, F. Buffolo, L. Gabetti, G. Mengozzi, T.A. Williams, F. Rabbia, F. Veglio, P. Mulatero, Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 69(14), 1811–1820 (2017)CrossRef
3.
go back to reference Y. Xu, L. Wang, J. He, Y. Bi, M. Li, T. Wang, L. Wang, Y. Jiang, M. Dai, J. Lu, M. Xu, Y. Li, N. Hu, J. Li, S. Mi, C.S. Chen, G. Li, Y. Mu, J. Zhao, L. Kong, J. Chen, S. Lai, W. Wang, W. Zhao, G. Ning, China noncommunicable disease surveillance g. prevalence and control of diabetes in Chinese adults. JAMA 310(9), 948–959 (2013)CrossRef Y. Xu, L. Wang, J. He, Y. Bi, M. Li, T. Wang, L. Wang, Y. Jiang, M. Dai, J. Lu, M. Xu, Y. Li, N. Hu, J. Li, S. Mi, C.S. Chen, G. Li, Y. Mu, J. Zhao, L. Kong, J. Chen, S. Lai, W. Wang, W. Zhao, G. Ning, China noncommunicable disease surveillance g. prevalence and control of diabetes in Chinese adults. JAMA 310(9), 948–959 (2013)CrossRef
4.
go back to reference T. Wang, J. Lu, Q. Su, Y. Chen, Y. Bi, Y. Mu, L. Chen, R. Hu, X. Tang, X. Yu, M. Li, M. Xu, Y. Xu, Z. Zhao, L. Yan, G. Qin, Q. Wan, G. Chen, M. Dai, D. Zhang, Z. Gao, G. Wang, F. Shen, Z. Luo, Y. Qin, L. Chen, Y. Huo, Q. Li, Z. Ye, Y. Zhang, C. Liu, Y. Wang, S. Wu, T. Yang, H. Deng, D. Li, S. Lai, Z.T. Bloomgarden, L. Shi, G. Ning, J. Zhao, W. Wang, Group C.S. Ideal cardiovascular health metrics and major cardiovascular events in patients with prediabetes and diabetes. JAMA Cardiol. 4(9), 874–883 (2019) T. Wang, J. Lu, Q. Su, Y. Chen, Y. Bi, Y. Mu, L. Chen, R. Hu, X. Tang, X. Yu, M. Li, M. Xu, Y. Xu, Z. Zhao, L. Yan, G. Qin, Q. Wan, G. Chen, M. Dai, D. Zhang, Z. Gao, G. Wang, F. Shen, Z. Luo, Y. Qin, L. Chen, Y. Huo, Q. Li, Z. Ye, Y. Zhang, C. Liu, Y. Wang, S. Wu, T. Yang, H. Deng, D. Li, S. Lai, Z.T. Bloomgarden, L. Shi, G. Ning, J. Zhao, W. Wang, Group C.S. Ideal cardiovascular health metrics and major cardiovascular events in patients with prediabetes and diabetes. JAMA Cardiol. 4(9), 874–883 (2019)
5.
go back to reference A. Saiki, M. Otsuki, D. Tamada, T. Kitamura, I. Shimomura, I. Kurihara, T. Ichijo, Y. Takeda, T. Katabami, M. Tsuiki, N. Wada, T. Yanase, Y. Ogawa, J. Kawashima, M. Sone, N. Inagaki, T. Yoshimoto, R. Okamoto, K. Takahashi, H. Kobayashi, K. Tamura, K. Kamemura, K. Yamamoto, S. Izawa, M. Kakutani, M. Yamada, A. Tanabe, M. Naruse, Group J.J.S. Diabetes mellitus itself increases cardio-cerebrovascular risk and renal complications in primary aldosteronism. J. Clin. Endocrinol. Metab. 105(7), dgaa177 (2020) A. Saiki, M. Otsuki, D. Tamada, T. Kitamura, I. Shimomura, I. Kurihara, T. Ichijo, Y. Takeda, T. Katabami, M. Tsuiki, N. Wada, T. Yanase, Y. Ogawa, J. Kawashima, M. Sone, N. Inagaki, T. Yoshimoto, R. Okamoto, K. Takahashi, H. Kobayashi, K. Tamura, K. Kamemura, K. Yamamoto, S. Izawa, M. Kakutani, M. Yamada, A. Tanabe, M. Naruse, Group J.J.S. Diabetes mellitus itself increases cardio-cerebrovascular risk and renal complications in primary aldosteronism. J. Clin. Endocrinol. Metab. 105(7), dgaa177 (2020)
6.
go back to reference V.C. Wu, S.J. Chueh, L. Chen, C.H. Chang, Y.H. Hu, Y.H. Lin, K.D. Wu, W.S. Yang, T.S. Group, Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J. Hypertens. 35(8), 1698–1708 (2017)CrossRef V.C. Wu, S.J. Chueh, L. Chen, C.H. Chang, Y.H. Hu, Y.H. Lin, K.D. Wu, W.S. Yang, T.S. Group, Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J. Hypertens. 35(8), 1698–1708 (2017)CrossRef
7.
go back to reference G. Colussi, C. Catena, R. Lapenna, E. Nadalini, A. Chiuch, L.A. Sechi, Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30(9), 2349–2354 (2007)CrossRef G. Colussi, C. Catena, R. Lapenna, E. Nadalini, A. Chiuch, L.A. Sechi, Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30(9), 2349–2354 (2007)CrossRef
8.
go back to reference G. Giacchetti, V. Ronconi, F. Turchi, L. Agostinelli, F. Mantero, S. Rilli, M. Boscaro, Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J. Hypertens. 25(1), 177–186 (2007)CrossRef G. Giacchetti, V. Ronconi, F. Turchi, L. Agostinelli, F. Mantero, S. Rilli, M. Boscaro, Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J. Hypertens. 25(1), 177–186 (2007)CrossRef
9.
go back to reference M. Kaga, T. Utsumi, T. Tanaka, T. Kono, H. Nagano, K. Kawamura, N. Kamiya, T. Imamoto, N. Nihei, Y. Naya, H. Suzuki, T. Ichikawa, Risk of new-onset dyslipidemia after laparoscopic adrenalectomy in patients with primary aldosteronism. World J. Surg. 39(12), 2935–2940 (2015)CrossRef M. Kaga, T. Utsumi, T. Tanaka, T. Kono, H. Nagano, K. Kawamura, N. Kamiya, T. Imamoto, N. Nihei, Y. Naya, H. Suzuki, T. Ichikawa, Risk of new-onset dyslipidemia after laparoscopic adrenalectomy in patients with primary aldosteronism. World J. Surg. 39(12), 2935–2940 (2015)CrossRef
10.
go back to reference E. Fischer, C. Adolf, A. Pallauf, C. Then, M. Bidlingmaier, F. Beuschlein, J. Seissler, M. Reincke, Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J. Clin. Endocrinol. Metab. 98(6), 2513–2520 (2013)CrossRef E. Fischer, C. Adolf, A. Pallauf, C. Then, M. Bidlingmaier, F. Beuschlein, J. Seissler, M. Reincke, Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J. Clin. Endocrinol. Metab. 98(6), 2513–2520 (2013)CrossRef
11.
go back to reference J.R. Sowers, A. Whaley-Connell, M. Epstein, Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern Med 150(11), 776–783 (2009)CrossRef J.R. Sowers, A. Whaley-Connell, M. Epstein, Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern Med 150(11), 776–783 (2009)CrossRef
12.
go back to reference C. Adolf, E. Asbach, A.S. Dietz, K. Lang, S. Hahner, M. Quinkler, L.C. Rump, M. Bidlingmaier, M. Treitl, R. Ladurner, F. Beuschlein, M. Reincke, Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine 54(1), 198–205 (2016)CrossRef C. Adolf, E. Asbach, A.S. Dietz, K. Lang, S. Hahner, M. Quinkler, L.C. Rump, M. Bidlingmaier, M. Treitl, R. Ladurner, F. Beuschlein, M. Reincke, Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine 54(1), 198–205 (2016)CrossRef
13.
go back to reference H.M. Jin, D.C. Zhou, H.F. Gu, Q.Y. Qiao, S.K. Fu, X.L. Liu, Y. Pan, Antioxidant N-acetylcysteine protects pancreatic beta-cells against aldosterone-induced oxidative stress and apoptosis in female db/db mice and insulin-producing MIN6 cells. Endocrinology 154(11), 4068–4077 (2013)CrossRef H.M. Jin, D.C. Zhou, H.F. Gu, Q.Y. Qiao, S.K. Fu, X.L. Liu, Y. Pan, Antioxidant N-acetylcysteine protects pancreatic beta-cells against aldosterone-induced oxidative stress and apoptosis in female db/db mice and insulin-producing MIN6 cells. Endocrinology 154(11), 4068–4077 (2013)CrossRef
14.
go back to reference J. Gerards, D.A. Heinrich, C. Adolf, C. Meisinger, W. Rathmann, L. Sturm, N. Nirschl, M. Bidlingmaier, F. Beuschlein, B. Thorand, A. Peters, M. Reincke, M. Roden, M. Quinkler, Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion. J. Clin. Endocrinol. Metab. 104(8), 3192–3202 (2019)CrossRef J. Gerards, D.A. Heinrich, C. Adolf, C. Meisinger, W. Rathmann, L. Sturm, N. Nirschl, M. Bidlingmaier, F. Beuschlein, B. Thorand, A. Peters, M. Reincke, M. Roden, M. Quinkler, Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion. J. Clin. Endocrinol. Metab. 104(8), 3192–3202 (2019)CrossRef
15.
go back to reference J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata, M. Stowasser, W.F. Young Jr., The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101(5), 1889–1916 (2016)CrossRef J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata, M. Stowasser, W.F. Young Jr., The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101(5), 1889–1916 (2016)CrossRef
16.
go back to reference Y. Jiang, C. Zhang, W. Wang, T. Su, W. Zhou, L. Jiang, W. Zhu, J. Xie, G. Ning, Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism. J. Clin. Endocrinol. Metab. 100(5), 1837–1844 (2015)CrossRef Y. Jiang, C. Zhang, W. Wang, T. Su, W. Zhou, L. Jiang, W. Zhu, J. Xie, G. Ning, Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism. J. Clin. Endocrinol. Metab. 100(5), 1837–1844 (2015)CrossRef
17.
go back to reference Y. Jiang, C. Zhang, L. Ye, T. Su, W. Zhou, L. Jiang, Y. Zhang, W. Wang, Factors affecting parathyroid hormone levels in different types of primary aldosteronism. Clin. Endocrinol. (Oxf.) 85(2), 267–274 (2016)CrossRef Y. Jiang, C. Zhang, L. Ye, T. Su, W. Zhou, L. Jiang, Y. Zhang, W. Wang, Factors affecting parathyroid hormone levels in different types of primary aldosteronism. Clin. Endocrinol. (Oxf.) 85(2), 267–274 (2016)CrossRef
18.
go back to reference L. Xiao, Y. Jiang, C. Zhang, L. Jiang, W. Zhou, T. Su, G. Ning, W. Wang, A novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism. Clin. Endocrinol. (Oxf.) 90(6), 781–788 (2019)CrossRef L. Xiao, Y. Jiang, C. Zhang, L. Jiang, W. Zhou, T. Su, G. Ning, W. Wang, A novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism. Clin. Endocrinol. (Oxf.) 90(6), 781–788 (2019)CrossRef
19.
go back to reference American Diabetes A, Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1), S62–69 (2010)CrossRef American Diabetes A, Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1), S62–69 (2010)CrossRef
20.
go back to reference K. Murase, R. Nagaishi, H. Takenoshita, T. Nomiyama, Y. Akehi, T. Yanase, Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. Endocr. J. 60(8), 967–976 (2013)CrossRef K. Murase, R. Nagaishi, H. Takenoshita, T. Nomiyama, Y. Akehi, T. Yanase, Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. Endocr. J. 60(8), 967–976 (2013)CrossRef
21.
go back to reference F. Fallo, F. Veglio, C. Bertello, N. Sonino, P. Della Mea, M. Ermani, F. Rabbia, G. Federspil, P. Mulatero, Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 91(2), 454–459 (2006)CrossRef F. Fallo, F. Veglio, C. Bertello, N. Sonino, P. Della Mea, M. Ermani, F. Rabbia, G. Federspil, P. Mulatero, Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 91(2), 454–459 (2006)CrossRef
22.
go back to reference M. Reincke, C. Meisinger, R. Holle, M. Quinkler, S. Hahner, F. Beuschlein, M. Bidlingmaier, J. Seissler, S. Endres, Participants of the German Conn’s R. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm. Metab. Res 42(6), 435–439 (2010)CrossRef M. Reincke, C. Meisinger, R. Holle, M. Quinkler, S. Hahner, F. Beuschlein, M. Bidlingmaier, J. Seissler, S. Endres, Participants of the German Conn’s R. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm. Metab. Res 42(6), 435–439 (2010)CrossRef
23.
go back to reference J.M. Luther, Effects of aldosterone on insulin sensitivity and secretion. Steroids 91, 54–60 (2014)CrossRef J.M. Luther, Effects of aldosterone on insulin sensitivity and secretion. Steroids 91, 54–60 (2014)CrossRef
24.
go back to reference L.M. Mosso, C.A. Carvajal, A. Maiz, E.H. Ortiz, C.R. Castillo, R.A. Artigas, C.E. Fardella, A possible association between primary aldosteronism and a lower beta-cell function. J. hypertension 25(10), 2125–2130 (2007)CrossRef L.M. Mosso, C.A. Carvajal, A. Maiz, E.H. Ortiz, C.R. Castillo, R.A. Artigas, C.E. Fardella, A possible association between primary aldosteronism and a lower beta-cell function. J. hypertension 25(10), 2125–2130 (2007)CrossRef
25.
go back to reference K. Shimamoto, M. Shiiki, T. Ise, Y. Miyazaki, K. Higashiura, M. Fukuoka, A. Hirata, A. Masuda, M. Nakagawa, O. Iimura, Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J. Hum. Hypertension 8(10), 755–759 (1994) K. Shimamoto, M. Shiiki, T. Ise, Y. Miyazaki, K. Higashiura, M. Fukuoka, A. Hirata, A. Masuda, M. Nakagawa, O. Iimura, Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J. Hum. Hypertension 8(10), 755–759 (1994)
26.
go back to reference Y. Akehi, T. Yanase, R. Motonaga, H. Umakoshi, M. Tsuiki, Y. Takeda, T. Yoneda, I. Kurihara, H. Itoh, T. Katabami, T. Ichijo, N. Wada, Y. Shibayama, T. Yoshimoto, K. Ashida, Y. Ogawa, J. Kawashima, M. Sone, N. Inagaki, K. Takahashi, M. Fujita, M. Watanabe, Y. Matsuda, H. Kobayashi, H. Shibata, K. Kamemura, M. Otsuki, Y. Fujii, K. Yamamoto, A. Ogo, S. Okamura, S. Miyauchi, T. Fukuoka, S. Izawa, S. Hashimoto, M. Yamada, Y. Yoshikawa, T. Kai, T. Suzuki, T. Kawamura, M. Naruse, Japan Primary Aldosteronism Study G. High Prevalence of Diabetes in Patients With Primary Aldosteronism (PA) Associated With Subclinical Hypercortisolism and Prediabetes More Prevalent in Bilateral Than Unilateral PA: A Large, Multicenter Cohort Study in Japan. Diabetes Care 42(5), 938–945 (2019)CrossRef Y. Akehi, T. Yanase, R. Motonaga, H. Umakoshi, M. Tsuiki, Y. Takeda, T. Yoneda, I. Kurihara, H. Itoh, T. Katabami, T. Ichijo, N. Wada, Y. Shibayama, T. Yoshimoto, K. Ashida, Y. Ogawa, J. Kawashima, M. Sone, N. Inagaki, K. Takahashi, M. Fujita, M. Watanabe, Y. Matsuda, H. Kobayashi, H. Shibata, K. Kamemura, M. Otsuki, Y. Fujii, K. Yamamoto, A. Ogo, S. Okamura, S. Miyauchi, T. Fukuoka, S. Izawa, S. Hashimoto, M. Yamada, Y. Yoshikawa, T. Kai, T. Suzuki, T. Kawamura, M. Naruse, Japan Primary Aldosteronism Study G. High Prevalence of Diabetes in Patients With Primary Aldosteronism (PA) Associated With Subclinical Hypercortisolism and Prediabetes More Prevalent in Bilateral Than Unilateral PA: A Large, Multicenter Cohort Study in Japan. Diabetes Care 42(5), 938–945 (2019)CrossRef
27.
go back to reference G.K. Adler, G.R. Murray, A.F. Turcu, H. Nian, C. Yu, C.C. Solorzano, R. Manning, D. Peng, J.M. Luther, Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans. Hypertension 75(5), 1251–1259 (2020)CrossRef G.K. Adler, G.R. Murray, A.F. Turcu, H. Nian, C. Yu, C.C. Solorzano, R. Manning, D. Peng, J.M. Luther, Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans. Hypertension 75(5), 1251–1259 (2020)CrossRef
28.
go back to reference G. Danaei, C.M. Lawes, S. Vander Hoorn, C.J. Murray, M. Ezzati, Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 368(9548), 1651–1659 (2006)CrossRef G. Danaei, C.M. Lawes, S. Vander Hoorn, C.J. Murray, M. Ezzati, Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 368(9548), 1651–1659 (2006)CrossRef
29.
go back to reference G.P. Rossi, Primary aldosteronism: JACC state-of-the-art review. J. Am. Coll. Cardiol. 74(22), 2799–2811 (2019)CrossRef G.P. Rossi, Primary aldosteronism: JACC state-of-the-art review. J. Am. Coll. Cardiol. 74(22), 2799–2811 (2019)CrossRef
30.
go back to reference J.J. Joseph, J.B. Echouffo-Tcheugui, R.R. Kalyani, H.C. Yeh, A.G. Bertoni, V.S. Effoe, R. Casanova, M. Sims, A. Correa, W.C. Wu, G.S. Wand, S.H. Golden, Aldosterone, renin, and diabetes mellitus in African Americans: the Jackson heart study. J. Clin. Endocrinol. Metab. 101(4), 1770–1778 (2016)CrossRef J.J. Joseph, J.B. Echouffo-Tcheugui, R.R. Kalyani, H.C. Yeh, A.G. Bertoni, V.S. Effoe, R. Casanova, M. Sims, A. Correa, W.C. Wu, G.S. Wand, S.H. Golden, Aldosterone, renin, and diabetes mellitus in African Americans: the Jackson heart study. J. Clin. Endocrinol. Metab. 101(4), 1770–1778 (2016)CrossRef
31.
go back to reference M. Murata, T. Kitamura, D. Tamada, K. Mukai, S. Kurebayashi, T. Yamamoto, K. Hashimoto, R.D. Hayashi, H. Kouhara, S. Takeiri, Y. Kajimoto, M. Nakao, T. Hamasaki, M. Otsuki, I. Shimomura, Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. J. Hypertens. 35(5), 1079–1085 (2017)CrossRef M. Murata, T. Kitamura, D. Tamada, K. Mukai, S. Kurebayashi, T. Yamamoto, K. Hashimoto, R.D. Hayashi, H. Kouhara, S. Takeiri, Y. Kajimoto, M. Nakao, T. Hamasaki, M. Otsuki, I. Shimomura, Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. J. Hypertens. 35(5), 1079–1085 (2017)CrossRef
32.
go back to reference Z. Xu, J. Yang, J. Hu, Y. Song, W. He, T. Luo, Q. Cheng, L. Ma, R. Luo, P.J. Fuller, J. Cai, Q. Li, S. Yang, Chongqing primary aldosteronism study G primary aldosteronism in patients in china with recently detected hypertension. J. Am. Coll. Cardiol. 75(16), 1913–1922 (2020)CrossRef Z. Xu, J. Yang, J. Hu, Y. Song, W. He, T. Luo, Q. Cheng, L. Ma, R. Luo, P.J. Fuller, J. Cai, Q. Li, S. Yang, Chongqing primary aldosteronism study G primary aldosteronism in patients in china with recently detected hypertension. J. Am. Coll. Cardiol. 75(16), 1913–1922 (2020)CrossRef
Metadata
Title
Newly diagnosed diabetes mellitus is a risk factor for cardiocerebrovascular events in primary aldosteronism
Authors
Cui Zhang
Yiran Jiang
Tingwei Su
Lei Jiang
Weiwei Zhou
Xu Zhong
Luming Wu
Weiqing Wang
Publication date
29-07-2022
Publisher
Springer US
Published in
Endocrine / Issue 3/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03095-8

Other articles of this Issue 3/2022

Endocrine 3/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine